-
Something wrong with this record ?
Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer
R. Hrstka, M. Beránek, K. Klocová, R. Nenutil, B. Vojtěšek
Language English Country Greece
Document type Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2006 to 1 year ago
- MeSH
- Adult MeSH
- Carcinoma, Ductal, Breast genetics metabolism secondary MeSH
- Gene Frequency MeSH
- Immunoenzyme Techniques MeSH
- Introns genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Carcinoma, Lobular genetics metabolism secondary MeSH
- Lymphatic Metastasis MeSH
- Young Adult MeSH
- Mutation genetics MeSH
- Biomarkers, Tumor genetics metabolism MeSH
- Tumor Suppressor Protein p53 genetics MeSH
- Breast Neoplasms genetics metabolism pathology MeSH
- Polymerase Chain Reaction MeSH
- Polymorphism, Restriction Fragment Length MeSH
- Polymorphism, Genetic MeSH
- Prognosis MeSH
- Breast metabolism pathology MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
Recent studies have suggested that genetic polymorphisms in the TP53 pathway influence tumour formation, progression and response to therapy. We analysed the three most common TP53 gene polymorphisms as potential genetic markers to predict the development and prognosis of breast cancer. The incidence of R72P, PIN3 Ins 16bp and PIN6 G13494A polymorphisms was determined in a cohort of 117 breast cancer tissues and 108 control specimens by PCR-RFLP. No significant difference was observed in the polymorphism variants in breast cancer specimens compared to controls. Furthermore, no statistically significant association of these polymorphisms with the outcome of the patients was observed. On the other hand we found positive correlation of lymph node metastases with both PIN3 Ins 16bp and PIN6 G13494A polymorphisms. The association of intronic TP53 variants with an aggressive breast cancer phenotype may represent a useful predictive biomarker, particularly in patients of clinical stage I with low or intermediate risk.
- 000
- 03270naa 2200613 a 4500
- 001
- bmc11022336
- 003
- CZ-PrNML
- 005
- 20120420144736.0
- 008
- 110729s2009 gr e Eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Hrstka, Roman $7 xx0077297
- 245 10
- $a Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer / $c R. Hrstka, M. Beránek, K. Klocová, R. Nenutil, B. Vojtěšek
- 314 __
- $a Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
- 520 9_
- $a Recent studies have suggested that genetic polymorphisms in the TP53 pathway influence tumour formation, progression and response to therapy. We analysed the three most common TP53 gene polymorphisms as potential genetic markers to predict the development and prognosis of breast cancer. The incidence of R72P, PIN3 Ins 16bp and PIN6 G13494A polymorphisms was determined in a cohort of 117 breast cancer tissues and 108 control specimens by PCR-RFLP. No significant difference was observed in the polymorphism variants in breast cancer specimens compared to controls. Furthermore, no statistically significant association of these polymorphisms with the outcome of the patients was observed. On the other hand we found positive correlation of lymph node metastases with both PIN3 Ins 16bp and PIN6 G13494A polymorphisms. The association of intronic TP53 variants with an aggressive breast cancer phenotype may represent a useful predictive biomarker, particularly in patients of clinical stage I with low or intermediate risk.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a prsy $x metabolismus $x patologie $7 D001940
- 650 _2
- $a nádory prsu $x genetika $x metabolismus $x patologie $7 D001943
- 650 _2
- $a duktální karcinom prsu $x genetika $x metabolismus $x sekundární $7 D018270
- 650 _2
- $a lobulární karcinom $x genetika $x metabolismus $x sekundární $7 D018275
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a frekvence genu $7 D005787
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoenzymatické techniky $7 D007124
- 650 _2
- $a introny $x genetika $7 D007438
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $x genetika $7 D009154
- 650 _2
- $a polymerázová řetězová reakce $7 D016133
- 650 _2
- $a polymorfismus genetický $7 D011110
- 650 _2
- $a polymorfismus délky restrikčních fragmentů $7 D012150
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a nádorové biomarkery $x genetika $x metabolismus $7 D014408
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1#
- $a Beránek, Michal. $7 xx0193695
- 700 1#
- $a Klocová, Kateřina. $7 _AN042044
- 700 1_
- $a Nenutil, Rudolf $7 xx0057842
- 700 1_
- $a Vojtěšek, Bořivoj, $d 1960- $7 xx0001694
- 773 0_
- $t Oncology Reports $w MED00179060 $g Roč. 22, č. 5 (2009), s. 1205-1211 $x 1021-335X
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110801132905 $b ABA008
- 991 __
- $a 20120420144710 $b ABA008
- 999 __
- $a ok $b bmc $g 881728 $s 732255
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00179060 $b 22 $c 5 $d 1205-1211 $i 1021-335X $m Oncology reports $n Oncol Rep
- LZP __
- $a 2011-4B09/jvme
